- Home
- MFIN vs CGEN Comparison
MFIN vs CGEN Comparison
Compare MFIN & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | CGEN |
|---|---|---|
| Founded | 1995 | 1993 |
| Country | United States | Israel |
| Employees | 179 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.0M | 191.1M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | MFIN | CGEN |
|---|---|---|
| Price | $10.94 | $2.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $5.00 |
| AVG Volume (30 Days) | 40.4K | ★ 235.0K |
| Earning Date | 04-29-2026 | 05-18-2026 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.02 | $75.09 |
| P/E Ratio | $6.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $1.30 |
| 52 Week High | $11.05 | $3.24 |
Technical Indicators
Market Signals| Indicator | MFIN | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 67.98 | 48.70 |
| Support Level | $9.20 | $2.22 |
| Resistance Level | N/A | $2.35 |
| Average True Range (ATR) | 0.32 | 0.12 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 87.19 | 37.14 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.